Evidence map›Paper›PMID 35509443›Full record

ArticleERJ open research2022

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.

Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M Hammitt, Michael Kreuter, Teng Moua, Emily C O'Brien and 8 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cough in Fibrotic Interstitial Lung Disease: Effects and Implications.American journal of respiratory and critical care medicine · 2024
    Article
  9. Validation of a Novel Clinical Dyspnea Scale - A Retrospective Pilot Study.The American journal of hospice & palliative care · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 6 countries.

Marlies WijsenbeekDept of Respiratory Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Maria Molina-MolinaDept of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Institute for Biomedical Research (IDIBELL), Barcelona, Spain.
Olivier ChassanyPatient-Reported Outcomes Research Unit, Université de Paris, Paris, France.
John FoxFoxworthy Healthcare Consulting, Ada, MI, USA.
Liam GalvinEuropean Idiopathic Pulmonary Fibrosis and Related Disorders Federation, Overijse, Belgium.
Klaus GeisslerPatient Support Group, Lungenfibrose eV, Essen, Germany.
Katherine M HammittSjögren's Foundation, Reston, VA, USA.
Michael KreuterCenter for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-4402-2159
Teng MouaDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Emily C O'BrienDuke Clinical Research Institute, Durham, NC, USA.
Ashley F SlagleAspen Consulting, LLC, Steamboat Springs, CO, USA.ORCID https://orcid.org/0000-0001-5651-8042
Anna KrasnowPatient Centred Solutions, IQVIA, London, UK.
Matthew ReaneyPatient Centred Solutions, IQVIA, Reading, UK.
Michael BaldwinBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Natalia MaleBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Klaus B RohrBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Jeff SwigrisNational Jewish Health, Denver, CO, USA.
Katerina AntoniouLaboratory of Cellular and Molecular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Crete, Greece.
Boehringer Ingelheim (Germany) · DEIQVIA (United Kingdom) · GBClinical Research Institute · USHeidelberg University · DEInstitut d'Investigació Biomédica de Bellvitge · ESMayo Clinic · USNational Jewish Health · USRome Foundation · USUniversité Paris Cité · FRUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. Methods: A systematic literature review was conducted to develop a preliminary conceptual model of the symptoms experienced by patients with PF-ILD and the impacts the disease has on them. An online survey and consensus meetings were then conducted with 12-14 stakeholders (patients, clinicians, regulatory and payer advisors) to refine the conceptual model and critically appraise how key concepts should be measured by PROMs. PROMs assessed included Living with Idiopathic Pulmonary Fibrosis, Living with Pulmonary Fibrosis, the King's Brief Interstitial Lung Disease questionnaire, Cough and Sputum Assessment Questionnaire, Evaluating Respiratory Symptoms, Leicester Cough Questionnaire, Functional Assessment of Chronic Illness Therapy (Dyspnoea/Fatigue) and St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis. Results: The literature review identified 36 signs/symptoms and 43 impacts directly or indirectly related to pulmonary aspects of PF-ILD. The most relevant symptoms identified by participants included shortness of breath on exertion, fatigue and cough; relevant impacts included effects on physical functioning, activities of daily living and emotional wellbeing. These are presented in a conceptual model. Consensus opinion was that existing PROMs need further modification and validation before use in clinical trials. Conclusions: The conceptual model improves understanding of the symptoms and impacts that living with PF-ILD has on patients' wellbeing. It can help to inform the choice of PROMs in clinical trials and highlight aspects to assess in the clinical care of patients with PF-ILD.

Identifiers

PMID35509443
PMCPMC9062300
OpenAlexW4224236065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.